178493

Apoptosis Activator III, Embelin

The Apoptosis Activator III, Embelin, also referenced under CAS 550-24-3, controls the biological activity of Apoptosis. This small molecule/inhibitor is primarily used for Cancer applications.

• Synonym(e): Apoptosis Activator III, Embelin, Embelin, Embelia ribes, XIAP inhibitor, Embelin, 2,5-Dihydroxy-3-undecyl-1,4-benzoquinone
• Empirische Formel (Hill-System): C₁₇H₂₆O₄
• CAS-Nummer: 550-24-3
• Molekulargewicht: 294.39
• NACRES: NA.77
• UNSPSC Code: 12352200
• MDL number: MFCD00016369
• Form: solid
• Storage condition: OK to freeze, protect from light

Eigenschaften

• Quality Segment: 100
• form: solid
• manufacturer/tradename: Calbiochem^®
• storage condition: OK to freeze, protect from light
• color: orange
• solubility: DMSO: 10 mg/mL, methanol: 5 mg/mL
• shipped in: ambient
• storage temp.: 2-8°C
• InChI: 1S/C17H26O4/c1-2-3-4-5-6-7-8-9-10-11-13-16(20)14(18)12-15(19)17(13)21/h12,18,21H,2-11H2,1H3
• InChI key: IRSFLDGTOHBADP-UHFFFAOYSA-N

Beschreibung

General description

A cell-permeable benzoquinone compound that exhibits antitumor properties. Specifically antagonizes XIAP (X-linked inhibitor of apoptosis)-mediated inhibition of caspase-9 activation by directly targeting the Smac and caspase-9 binding domain BIR3 (IC₅₀ = 4.1 µM in a competitive binding assay with Smac peptide). Selectively induces caspase-9-mediated apoptosis in prostate cancer cells with high levels of XIAP (IC₅₀ = 3.7 and 5.7 µM for PC-3 and LnCap, respectively), while exhibiting much less effect towards cells with low level XIAP (IC₅₀ = 19.3 and 20.1 µM for WI-38 and PrEC, respectively). Also shown to sensitize XIAP overexpressing Jurkat cells to Etoposide -induced apoptosis. A non-competitive PCAF (p300/CBP associated factor)-specific lysine acetyltransferase (KAT) inhibitor (IC₅₀ = 7.2 µM).

A cell-permeable, benzoquinone compound that exhibits anti-tumor properties. Shown to specifically antagonize X-linked inhibitor of apoptosis- (XIAP) mediated inhibition of caspase-9 activation by directly targeting the Smac and caspase-9 binding domain BIR3 (IC₅₀ = 4.1 µM in a competitive binding assay using Smac peptide). Also selectively induces caspase-9-mediated apoptosis in prostate cancer cells expressing high levels of XIAP (IC₅₀ = 3.7 µM for PC-3 cells and 5.7 µM for LnCap cells), while exhibiting lesser effects toward cells with low levels of XIAP (IC₅₀ = 19.3 µM for WI-38 cells and 20.1 µM for PrEC cells). Reported to sensitize XIAP-overexpressing Jurkat cells to Etoposide- (Cat. No. 341245) induced apoptosis. A non-competitive PCAF (p300/CBP associated factor)-specific lysine acetyltransferase (KAT) inhibitor (IC₅₀ = 7.2 µM).

Biochem/physiol Actions

Cell permeable: yes

Primary Target
BIR3

Product does not compete with ATP.

Reversible: no

Target IC₅₀: 4.1 µM in antagonizing XIAP (X-linked inhibitor of apoptosis)-mediated inhibition of caspase-9 activation by directly targeting the Smac and caspase-9 binding domain BIR3 in a competitive binding assay with Smac peptide

Packaging

Packaged under inert gas

Analysis Note

Single spot by TLC

Other Notes

Modak, R., et al. 2013. ACS Chem. Biol.8, In press.
Nikolovska-Coleska, Z., et al. 2004. J. Med. Chem.47, 2430.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Standard Handling (A)

Sicherheitshinweise

• pictograms: GHS08
• signalword: Warning
• hcodes: H361f
• pcodes: P201 - P202 - P280 - P308 + P313 - P405 - P501
• Hazard Classifications: Repr. 2
• Lagerklasse: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable